Literature DB >> 19331516

Erythrocyte-bound tissue plasminogen activator is neuroprotective in experimental traumatic brain injury.

Sherman C Stein1, Kumkum Ganguly, Caitlin M Belfield, Xiangsheng Xu, Edward W Swanson, Xiao-Han Chen, Kevin D Browne, Victoria E Johnson, Douglas H Smith, David G LeBold, Douglas B Cines, Vladimir R Muzykantov, Vladimir R Muzykhantov.   

Abstract

The purpose of this study was to test the effects of exogenous tissue plasminogen activator (tPA) in traumatic brain injury (TBI).We tested two different tPA formulations, free tPA and tPA bound to erythrocytes (RBC/tPA).Vehicle and each of the tPA treatments were injected intravenously into anesthetized rats 15 min after moderate lateral fluid percussion injury. The animals were sacrificed at 2 days for calculating microclot burden (n=13) and IgG staining area (n=13) in the brain sections as indicators of post-traumatic thrombosis and blood-brain barrier (BBB) breakdown, respectively. Another set of injured animals treated in the same way were sacrificed at 7 days to compare cortical lesion volumes (n=28) and CA3 hippocampal cell loss (n=24). All evaluations were done blinded with respect to treatment. No significant differences were found with respect to microclot burden or IgG staining volume. Injection of wild-type tPA caused significantly ( p<0.05) larger cortical injuries and greater cerebral hemorrhage. In contrast, there was significantly less cortical injury ( p<0.01) and hippocampal cell loss ( p<0.01) in the RBC=tPA group than in all other groups. These results reveal that RBC/tPA is more neuroprotective in experimental TBI than is unbound tPA.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19331516      PMCID: PMC2766435          DOI: 10.1089/neu.2008.0720

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  26 in total

1.  Localization of human tissue factor antigen by immunostaining with monospecific, polyclonal anti-human tissue factor antibody.

Authors:  R A Fleck; L V Rao; S I Rapaport; N Varki
Journal:  Thromb Res       Date:  1990-07-15       Impact factor: 3.944

2.  Ischaemic brain damage in fatal head injuries.

Authors:  D I Graham; J H Adams
Journal:  Lancet       Date:  1971-02-06       Impact factor: 79.321

3.  Attachment of antibody to biotinylated red blood cells: immuno-red blood cells display high affinity to immobilized antigen and normal biodistribution in rats.

Authors:  V R Muzykantov; J C Murciano
Journal:  Biotechnol Appl Biochem       Date:  1996-08       Impact factor: 2.431

Review 4.  New functions for an old enzyme: nonhemostatic roles for tissue-type plasminogen activator in the central nervous system.

Authors:  Manuel Yepes; Daniel A Lawrence
Journal:  Exp Biol Med (Maywood)       Date:  2004-12

5.  Ischaemic brain damage is still common in fatal non-missile head injury.

Authors:  D I Graham; I Ford; J H Adams; D Doyle; G M Teasdale; A E Lawrence; D R McLellan
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-03       Impact factor: 10.154

6.  Prolonged and extensive IgG immunoreactivity after severe fluid-percussion injury in rat brain.

Authors:  S Hoshino; S Kobayashi; S Nakazawa
Journal:  Brain Res       Date:  1996-03-04       Impact factor: 3.252

7.  Traumatic brain injury in the rat: characterization of a lateral fluid-percussion model.

Authors:  T K McIntosh; R Vink; L Noble; I Yamakami; S Fernyak; H Soares; A L Faden
Journal:  Neuroscience       Date:  1989       Impact factor: 3.590

Review 8.  Craniocerebral trauma: protection and retrieval of the neuronal population after injury.

Authors:  G M Teasdale; D I Graham
Journal:  Neurosurgery       Date:  1998-10       Impact factor: 4.654

9.  Two receptor systems are involved in the plasma clearance of tissue-type plasminogen activator (t-PA) in vivo.

Authors:  M Narita; G Bu; J Herz; A L Schwartz
Journal:  J Clin Invest       Date:  1995-08       Impact factor: 14.808

10.  Atorvastatin reduction of intravascular thrombosis, increase in cerebral microvascular patency and integrity, and enhancement of spatial learning in rats subjected to traumatic brain injury.

Authors:  Dunyue Lu; Asim Mahmood; Anton Goussev; Timothy Schallert; Changsheng Qu; Zheng Gang Zhang; Yi Li; Mei Lu; Michael Chopp
Journal:  J Neurosurg       Date:  2004-11       Impact factor: 5.115

View more
  18 in total

Review 1.  Investigational agents for treatment of traumatic brain injury.

Authors:  Ye Xiong; Yanlu Zhang; Asim Mahmood; Michael Chopp
Journal:  Expert Opin Investig Drugs       Date:  2015-03-01       Impact factor: 6.206

2.  Red blood cell-coupled tissue plasminogen activator prevents impairment of cerebral vasodilatory responses through inhibition of c-Jun-N-terminal kinase and potentiation of p38 mitogen-activated protein kinase after cerebral photothrombosis in the newborn pig.

Authors:  William M Armstead; Kumkum Ganguly; John Riley; J Willis Kiessling; Douglas B Cines; Abd A R Higazi; Sergei Zaitsev; Vladimir R Muzykantov
Journal:  Pediatr Crit Care Med       Date:  2011-11       Impact factor: 3.624

3.  Flow-dependent channel formation in clots by an erythrocyte-bound fibrinolytic agent.

Authors:  Kathryn C Gersh; Sergei Zaitsev; Douglas B Cines; Vladimir Muzykantov; John W Weisel
Journal:  Blood       Date:  2011-03-09       Impact factor: 22.113

Review 4.  Vascular targeting of antithrombotic agents.

Authors:  Ronald Carnemolla; Vladimir R Muzykantov
Journal:  IUBMB Life       Date:  2011-07-15       Impact factor: 3.885

5.  Treatment of TBI with collagen scaffolds and human marrow stromal cells increases the expression of tissue plasminogen activator.

Authors:  Asim Mahmood; Changsheng Qu; Riuzuo Ning; Hongtao Wu; Anton Goussev; Ye Xiong; Susan Irtenkauf; Yi Li; Michael Chopp
Journal:  J Neurotrauma       Date:  2011-05-16       Impact factor: 5.269

Review 6.  Advanced drug delivery systems for antithrombotic agents.

Authors:  Colin F Greineder; Melissa D Howard; Ronald Carnemolla; Douglas B Cines; Vladimir R Muzykantov
Journal:  Blood       Date:  2013-06-24       Impact factor: 22.113

Review 7.  Signaling, delivery and age as emerging issues in the benefit/risk ratio outcome of tPA For treatment of CNS ischemic disorders.

Authors:  William M Armstead; Kumkum Ganguly; J W Kiessling; John Riley; Xiao-Han Chen; Douglas H Smith; Sherman C Stein; Abd A R Higazi; Douglas B Cines; Khalil Bdeir; Sergei Zaitsev; Vladimir R Muzykantov
Journal:  J Neurochem       Date:  2010-04       Impact factor: 5.372

Review 8.  Delivery of drugs bound to erythrocytes: new avenues for an old intravascular carrier.

Authors:  Carlos H Villa; Daniel C Pan; Sergei Zaitsev; Douglas B Cines; Donald L Siegel; Vladimir R Muzykantov
Journal:  Ther Deliv       Date:  2015-07

Review 9.  Red blood cells: Supercarriers for drugs, biologicals, and nanoparticles and inspiration for advanced delivery systems.

Authors:  Carlos H Villa; Aaron C Anselmo; Samir Mitragotri; Vladimir Muzykantov
Journal:  Adv Drug Deliv Rev       Date:  2016-03-03       Impact factor: 15.470

10.  Red blood cells-coupled tPA prevents impairment of cerebral vasodilatory responses and tissue injury in pediatric cerebral hypoxia/ischemia through inhibition of ERK MAPK activation.

Authors:  William M Armstead; Kumkum Ganguly; John W Kiessling; Xiao-Han Chen; Douglas H Smith; Abd A R Higazi; Douglas B Cines; Khalil Bdeir; Sergei Zaitsev; Vladimir R Muzykantov
Journal:  J Cereb Blood Flow Metab       Date:  2009-05-13       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.